Off-Patent Semaglutide in 2026: The Next Revolution in Anti-Obesity Medications

Semaglutide as Ozempic for Diabetes and Wegovy for weight-loss management, is the world’s second-best selling prescription medicine, with combined sales of $26bn in 2024 and growing annually at a staggering 40%.

In 2026, semaglutide faces loss of exclusivity in key markets, and is set to revolutionise the commercial and clinical landscape. In this session we will explore the implications for patient access, market dynamics, and treatment pathways where you gain a comprehensive understanding of how 2026 will shape the future of obesity treatments for years to come.